Optimind Pharma Announces Adoption of Semi-Annual Reporting
Toronto, Ontario--(Newsfile Corp. - July 24, 2026) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntari
Biotechnologies, Cannabis, Santé, Psychédéliques
2026-07-24 9:04 AM EDT | Optimind Pharma Corp.
TelyRx to Host Second Quarter 2026 Financial Results Conference Call on Monday, August 10, 2026 at 8:30 am ET
Clearwater, Florida--(Newsfile Corp. - July 24, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its second quarter 2026 financial results on Monday, August 10, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its second quarter 2026 financial results for the period ended
Soins de santé et hôpitaux, Santé
2026-07-24 7:35 AM EDT | TelyRx
One Hemp Welcomes Bipartisan Push for Common-Sense Hemp Regulation
Washington, D.C.--(Newsfile Corp. - July 23, 2026) - ONE HEMP, a national coalition representing responsible hemp businesses and advocates, today welcomed the introduction of the bipartisan Lawful Hemp Protection Act, introduced by Reps. Andy Barr (R-KY) and Angie Craig (D-MN), calling it a significant step toward a responsible, federally regulated hemp marketplace that protects consumers without dismantling a vital American industry. The bill would establish federal standards for hemp
2026-07-23 8:08 AM EDT | OneHemp
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Ad hoc announcement pursuant to Art. 53 LR Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe Debt-free with more than €205 million in cash, cash equivalents and investments
Soins de santé et hôpitaux, Santé
2026-07-23 1:01 AM EDT | Cosmo Pharmaceuticals N.V.
Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants. Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant,
Biotechnologies, Pharmaceutique, Santé
2026-07-22 4:50 PM EDT | Hemostemix Inc.
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its t
Technologies, Biotechnologies, Soins de santé et hôpitaux, Santé
2026-07-22 10:00 AM EDT | Breathe BioMedical Inc.
MNDR Wins 2026 Technology for Good Award, Featuring Aiko in Its AI Intelligent Healthcare Ecosystem
Singapore, Singapore--(Newsfile Corp. - July 22, 2026) - Mobile-health Network Solutions Inc. (NASDAQ: MNDR) ("MNDR"), an AI-powered intelligent healthcare ecosystem, today announced it has been awarded the 2026 Technology for Good Distinction Award, following its recognition in 2025. This year's award highlights MNDR's AI Intelligent Healthcare Ecosystem, anchored by Aiko — the Agentic Patient Companion. Powered by MNDR's proprietary PhiGPT clinical
2026-07-22 8:38 AM EDT | Mobile-health Network Solutions
Altrova Health Provides Corporate Update: New OTCQB Symbol, O-Spray Commercial Progress, Additional NIRLAB Device Sale, and Rapid Detection Strip Expansion
Toronto, Ontario--(Newsfile Corp. - July 22, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to provide shareholders with an update across several areas of its business. New OTCQB Trading Symbol The Company's common shares commenced trading on the OTCQB under the new ticker symbol "ATVHF," effective as of market open on July 17, 2026, replacing the Company's prior symbol "SSPLF." The change does
2026-07-22 7:08 AM EDT | Altrova Health Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 7:00 AM EDT | Phio Pharmaceuticals Corp.
Custom Health Announces Binding Letter of Intent to Acquire Evergreen Pharmacy; Expected to Add Over US$78 Million in Annual Revenue
Custom Health has entered into a binding letter of intent (the "LOI") to acquire Evergreen Pharmacy LLC ("Evergreen"), a Wisconsin-based specialty pharmacy specializing in the management of complex therapies for chronic disease states. Evergreen generated Revenue of approximately US$78.8 million with Normalized EBITDA (1) of US$0.60 million, for the twelve-month period ended December 31, 2025. Evergreen is a profitable company on both EBITDA an
Technologies, Pharmaceutique, Santé
2026-07-22 6:30 AM EDT | Custom Health Holdings Inc.
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, an
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-21 7:00 AM EDT | Phio Pharmaceuticals Corp.
CNA urges Premiers to act on nursing solutions for better care and stronger health systems
Charlottetown, Prince Edward Island--(Newsfile Corp. - July 21, 2026) - As Canada's premiers gather in Charlottetown for the Council of the Federation summer meeting, the Canadian Nurses Association (CNA) is urging them to act on proven solutions that can improve access to care, support the nursing workforce, and strengthen health systems for people across Canada. With demand rising and too many people waiting too long for care, premiers have an opportunity to act now. By updating polic
2026-07-21 6:00 AM EDT | Canadian Nurses Association | Association des infirmières et infirmiers du Canada
L'AIIC invite les premiers ministres à miser sur des solutions infirmières pour améliorer les soins et renforcer les systèmes de santé
Charlottetown, Île-du-Prince-Édouard--(Newsfile Corp. - 21 juillet 2026) - Alors que les premières ministres et premiers ministres du Canada se réunissent à Charlottetown à l'occasion de la réunion estivale du Conseil de la fédération, l'Association des infirmières et infirmiers du Canada (AIIC) les exhorte à mettre en œuvre des solutions éprouvées qui peuvent améliorer l'accès aux soins, soutenir la main-d'œuvre infir
2026-07-21 6:00 AM EDT | Canadian Nurses Association | Association des infirmières et infirmiers du Canada
Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is providing a corporate update regarding its upcoming expansion into the United States, the launch of an updated AI-driven e-commerce platform, and pipeline developments for its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The Company remains focused on scaling operations, driving revenue generation, and
Technologies, Biotechnologies, Santé
2026-07-21 6:00 AM EDT | Restart Life Sciences Corp.
Tersis Technologies Appoints Vaughan B. Adnams as Chief Investment & Capital Markets Officer
Brooksville, Florida--(Newsfile Corp. - July 20, 2026) - Tersis Technologies, Inc. (OTCID: TERS) ("Tersis" or the "Company"), a clean technology company advancing next generation waste-to-energy and resource recovery solutions, today announced the appointment of Vaughan B. Adnams as Chief Investment & Capital Markets Officer, effective immediately.
Agriculture, Énergie, Énergies de substitution, Santé
2026-07-20 11:51 AM EDT | Tersis Technologies Inc.
QScreen AI Deepens US Institutional Pipeline as Screening Platform Adds Escalation-Based Review Capability
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - QScreen AI Inc. (CSE: QAI) (OTC: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") today announced completion of the tiered screening architecture at the core of its commercialization strategy. The architecture is fully implemented in the Company's browser-based platform and is now being demonstrated to prospective institutional partners through the Company's US channel process, where a first signed evaluation agreement remains the stated
2026-07-20 7:01 AM EDT | QScreen AI Inc.
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
Houston, Texas--(Newsfile Corp. - July 20, 2026) - Alzheimer's disease is not only a scientific challenge; it is a human crisis affecting millions of patients, families, caregivers, and healthcare systems. Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) is responding through an intranasal nanoemulsion platform designed to explore new possibilities in neurodegenerative care through cannabinoid-based and natural-compound science. CBIH's invention centers on an intranasal me
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-07-20 7:00 AM EDT | Cannabis Bioscience International Holdings
LevelJump Announces Revocation of Cease Trade Order; Seeking Reinstatement of Trading on TSX Venture Exchange
Toronto, Ontario--(Newsfile Corp. - July 17, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce that, further to its news release of April 30, 2026, the Ontario Securities Commission has revoked a cease trade order that had been originally issued against the Company on May 6, 2026. The Company is now current on its continuous disclosure obligations under securities legislation. The Company is now in the process
Soins de santé et hôpitaux, Santé
2026-07-17 6:55 PM EDT | LevelJump Healthcare Corp.
Charlotte Janssen Announces Resignation as Independent Director of Metaguest.AI
Toronto, Ontario--(Newsfile Corp. - July 17, 2026) - Charlotte Janssen today announced her resignation as an independent director of Metaguest.AI Incorporated, a company listed on the Canadian Securities Exchange(the "Company"), effective immediately. After careful consideration, Ms. Janssen has concluded that it is no longer appropriate to continue serving on the Company's Board of Directors due to differing views regarding certain aspects of the Board's governance processes, de
Technologies, Construction / bâtiments, Santé, Juridique
2026-07-17 4:42 PM EDT | Charlotte Janssen